Biotechnology Value Fund and affiliated reporting persons amended a Schedule 13G/A to report their holdings in 4D Molecular Therapeutics as of March 31, 2026. The filing states the Reporting Persons hold Pre-Funded Warrants exercisable for an aggregate of 8,475,665 Shares, with the Pre-Funded Warrants Blocker limiting aggregate exercises to 2,467,230 Shares.
The filing discloses that BVF beneficially owned 3,907,517 Shares (≈7.3%), BVF2 beneficially owned 1,093,101 Shares (≈2.1%), Trading Fund OS beneficially owned 289,025 Shares (<1%), and that certain affiliated entities and persons may be deemed to beneficially own between 9.3% and 9.99% of outstanding Shares using the filing's denominator.
Positive
None.
Negative
None.
Insights
Grouped investment vehicles report concentrated holdings and exercise limits tied to pre-funded warrants.
The filing lists an aggregate of 8,475,665 Pre-Funded Warrants exercisable into common shares and a contractual cap (the Pre-Funded Warrants Blocker) that currently permits exercise of 2,467,230 Shares as of March 31, 2026. This constraint directly affects near-term potential dilution and voting/ownership thresholds disclosed.
Future changes in exercised warrants or the blocker waiver would be disclosed in subsequent statements; cash‑flow treatment and any exercise intentions are not stated in the provided excerpt.
Key Figures
Pre-Funded Warrants aggregate:8,475,665 sharesBlocker-limited exercises:2,467,230 sharesBVF beneficial ownership:3,907,517 shares+4 more
7 metrics
Pre-Funded Warrants aggregate8,475,665 sharesaggregate exercisable into common shares as of March 31, 2026
Blocker-limited exercises2,467,230 sharesmaximum exercisable under the Pre-Funded Warrants Blocker as of March 31, 2026
BVF beneficial ownership3,907,517 sharesBVF beneficially owned as of March 31, 2026 (≈7.3%)
BVF2 beneficial ownership1,093,101 sharesBVF2 beneficially owned as of March 31, 2026 (≈2.1%)
Trading Fund OS beneficial ownership289,025 sharesTrading Fund OS beneficially owned as of March 31, 2026 (<1%)
Shares outstanding used51,051,487 sharesShares outstanding as of March 16, 2026 used in percentage calculation
Aggregate reported by Partners/BVF Inc./Lampert5,346,519 sharesAggregate beneficial ownership that may be deemed by certain affiliates (≈9.99%)
"the Reporting Persons held certain Pre-Funded Warrants exercisable for an aggregate of 8,475,665 Shares"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Pre-Funded Warrants Blockerregulatory
"the Pre-Funded Warrants Blocker limits the aggregate exercise of the Pre-Funded Warrants held by the Reporting Persons"
Beneficially ownedfinancial
"BVF beneficially owned 3,907,517 Shares, including 2,467,230 Shares underlying certain Pre-Funded Warrants"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Partners Managed Accountfinancial
"the Reporting Persons and a certain Partners managed account (the "Partners Managed Account") held certain Pre-Funded Warrants"
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 7)
4D Molecular Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
35104E100
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
35104E100
1
Names of Reporting Persons
BIOTECHNOLOGY VALUE FUND L P
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,907,517.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,907,517.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,907,517.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.3 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
35104E100
1
Names of Reporting Persons
BVF I GP LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,907,517.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,907,517.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,907,517.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.3 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
35104E100
1
Names of Reporting Persons
BIOTECHNOLOGY VALUE FUND II LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,093,101.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,093,101.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,093,101.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.1 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
35104E100
1
Names of Reporting Persons
BVF II GP LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,093,101.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,093,101.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,093,101.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.1 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
35104E100
1
Names of Reporting Persons
Biotechnology Value Trading Fund OS LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
289,025.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
289,025.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
289,025.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.6 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
35104E100
1
Names of Reporting Persons
BVF Partners OS Ltd.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
289,025.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
289,025.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
289,025.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.6 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP Number(s):
35104E100
1
Names of Reporting Persons
BVF GP HOLDINGS LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
5,000,618.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
5,000,618.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
5,000,618.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.3 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
35104E100
1
Names of Reporting Persons
BVF PARTNERS L P/IL
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
5,346,519.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
5,346,519.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
5,346,519.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
IA, PN
SCHEDULE 13G
CUSIP Number(s):
35104E100
1
Names of Reporting Persons
BVF INC/IL
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
5,346,519.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
5,346,519.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
5,346,519.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP Number(s):
35104E100
1
Names of Reporting Persons
LAMPERT MARK N
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
5,346,519.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
5,346,519.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
5,346,519.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
4D Molecular Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
5858 Horton Street #455, Emeryville, CA 94608
Item 2.
(a)
Name of person filing:
Biotechnology Value Fund, L.P. ("BVF")
BVF I GP LLC ("BVF GP")
Biotechnology Value Fund II, L.P. ("BVF2")
BVF II GP LLC ("BVF2 GP")
Biotechnology Value Trading Fund OS LP ("Trading Fund OS")
BVF Partners OS Ltd. ("Partners OS")
BVF GP Holdings LLC ("BVF GPH")
BVF Partners L.P. ("Partners")
BVF Inc.
Mark N. Lampert ("Mr. Lampert")
Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."
(b)
Address or principal business office or, if none, residence:
Biotechnology Value Fund, L.P.
44 Montgomery St., 40th Floor
San Francisco, California 94104
BVF I GP LLC
44 Montgomery St., 40th Floor
San Francisco, California 94104
Biotechnology Value Fund II, L.P.
44 Montgomery St., 40th Floor
San Francisco, California 94104
BVF II GP LLC
44 Montgomery St., 40th Floor
San Francisco, California 94104
Biotechnology Value Trading Fund OS LP
PO Box 309 Ugland House
Grand Cayman, KY1-1104
Cayman Islands
BVF Partners OS Ltd.
PO Box 309 Ugland House
Grand Cayman, KY1-1104
Cayman Islands
BVF GP Holdings LLC
44 Montgomery St., 40th Floor
San Francisco, California 94104
BVF Partners L.P.
44 Montgomery St., 40th Floor
San Francisco, California 94104
BVF Inc.
44 Montgomery St., 40th Floor
San Francisco, California 94104
Mark N. Lampert
44 Montgomery St., 40th Floor
San Francisco, California 94104
(c)
Citizenship:
Biotechnology Value Fund, L.P.
Delaware
BVF I GP LLC
Delaware
Biotechnology Value Fund II, L.P.
Delaware
BVF II GP LLC
Delaware
Biotechnology Value Trading Fund OS LP
Cayman Islands
BVF Partners OS Ltd.
Cayman Islands
BVF GP Holdings LLC
Delaware
BVF Partners L.P.
Delaware
BVF Inc.
Delaware
Mark N. Lampert
United States
(d)
Title of class of securities:
Common Stock, par value $0.0001 per share
(e)
CUSIP No.:
35104E100
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
As of the close of business on March 31, 2026, the Reporting Persons and a certain Partners managed account (the "Partners Managed Account") held certain Pre-Funded Warrants (the "Pre-Funded Warrants") exercisable for an aggregate of 8,475,665 Shares. The Pre-Funded Warrants are exercisable at any time at an exercise price of $0.0001 per Share. A holder of Pre-Funded Warrants may not exercise any such Pre-Funded Warrants if upon giving effect to such exercise, it would cause the aggregate number of Shares beneficially owned by the holder (together with affiliates and any other persons whose beneficial ownership Shares would be aggregated for the purposes of Section 13(d) of the Exchange Act) to exceed 9.99% of the total number of then issued and outstanding Shares as determined in accordance with the terms of the Pre-Funded Warrants (the "Pre-Funded Warrants Blocker"). As of the close of business on March 31, 2026, the Pre-Funded Warrants Blocker limits the aggregate exercise of the Pre-Funded Warrants held by the Reporting Persons and the Partners Managed Account to 2,467,230 out of the 8,475,665 Shares underlying the Pre-Funded Warrants held by them.
As of the close of business on March 31, 2026, (i) BVF beneficially owned 3,907,517 Shares, including 2,467,230 Shares underlying certain Pre-Funded Warrants held by it and excluding 2,165,390 Shares underlying certain Pre-Funded Warrants held by it, (ii) BVF2 beneficially owned 1,093,101 Shares, excluding 3,319,994 Shares underlying the Pre-Funded Warrants held by it, and (iii) Trading Fund OS beneficially owned 289,025 Shares, excluding 410,036 Shares underlying the Pre-Funded Warrants held by it.
BVF GP, as the general partner of BVF, may be deemed to beneficially own the 3,907,517 Shares beneficially owned by BVF.
BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 1,093,101 Shares beneficially owned by BVF2.
Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 289,025 Shares beneficially owned by Trading Fund OS.
BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 5,000,618 Shares beneficially owned in the aggregate by BVF and BVF2.
Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 5,346,519 Shares beneficially owned in the aggregate by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, including 56,876 Shares held in the Partners Managed Account, which excludes 113,015 Shares underlying the Pre-Funded Warrants held in the Partners Managed Account.
BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 5,346,519 Shares beneficially owned by Partners.
Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 5,346,519 Shares beneficially owned by BVF Inc.
The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Shares owned by another Reporting Person. BVF GP disclaims beneficial ownership of the Shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the Shares beneficially owned by BVF2. Partners OS disclaims beneficial ownership of the Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the Shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Shares beneficially owned by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.
(b)
Percent of class:
The following percentages are based on a denominator that is the sum of: (i) 51,051,487 Shares outstanding as of March 16, 2026, as disclosed in the Issuer's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 18, 2026, and (ii) 2,467,230 Shares underlying certain Pre-Funded Warrants held by the Reporting Persons, as applicable.
As of the close of business on March 31, 2026, (i) BVF beneficially owned approximately 7.3% of the outstanding Shares, (ii) BVF2 beneficially owned approximately 2.1% of the outstanding Shares, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding Shares, (iv) BVF GP may be deemed to beneficially own approximately 7.3% of the outstanding Shares, (v) BVF2 GP may be deemed to beneficially own approximately 2.1% of the outstanding Shares, (vi) Partners OS may be deemed to beneficially own less than 1% of the outstanding Shares, (vii) BVF GPH may be deemed to beneficially own approximately 9.3% of the outstanding Shares and (viii) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 9.99% of the outstanding Shares (less than 1% of the outstanding Shares are held in the Partners Managed Account).
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See Cover Pages Items 5-9.
(ii) Shared power to vote or to direct the vote:
See Cover Pages Items 5-9.
(iii) Sole power to dispose or to direct the disposition of:
See Cover Pages Items 5-9.
(iv) Shared power to dispose or to direct the disposition of:
See Cover Pages Items 5-9.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
BVF GP, BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF. BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF2. Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by Trading Fund OS and held in the Partners Managed Account.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
See Exhibit 99.1 to the Schedule 13G filed with the Securities and Exchange Commission on July 6, 2021.
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
What stake does Biotechnology Value Fund (BVF) report in 4D Molecular Therapeutics (FDMT)?
BVF reports beneficial ownership of 3,907,517 Shares, representing approximately 7.3% of the class based on the filing's denominator. This count includes 2,467,230 Shares underlying exercisable pre-funded warrants subject to the filing's blocker limit.
How many Pre-Funded Warrants do the Reporting Persons hold in total?
The Reporting Persons and a Partners managed account hold an aggregate of 8,475,665 Pre-Funded Warrants exercisable for common shares. Contract terms limit aggregate exercise to 2,467,230 Shares under the stated blocker.
What is the "Pre-Funded Warrants Blocker" described in the filing?
The Pre-Funded Warrants Blocker is a contractual cap preventing exercise that would raise a holder's beneficial ownership above 9.99%. As of March 31, 2026, it limits the Reporting Persons to exercising 2,467,230 Shares of the warrants.
What aggregate ownership do BVF-affiliated entities report?
Affiliated entities and persons are reported as beneficially owning between 5,000,618 Shares (aggregate BVF and BVF2) and up to 5,346,519 Shares in the aggregate for Partners-held positions, with top-line percentages reported up to 9.99% using the filing's denominator.
What denominator did the filing use to calculate percentages?
Percentages use a denominator equal to 51,051,487 Shares outstanding as of March 16, 2026 plus 2,467,230 Shares underlying certain Pre-Funded Warrants, as stated in the filing's calculation.
